• Podcast What's behind PharmaMar's journey on the stock market?

PharmaMar

rides one more day on the Ibex 35 due to the results of its investigations against the coronavirus.

The latest findings recognized by the journal

Science

on the chemical compound

plitidepsin

are the reason that this Tuesday its shares rise more than 20% on the Madrid stock market and are above 108 euros.

The prestigious scientific publication has endorsed the "powerful" activity of this compound against Covid-19 in an article that states that the Spanish laboratory test showed a 99% decrease in the

viral loads of SARS-CoV-2 in the lungs

of the animals under study.

The magazine also emphasizes that the toxicity that this product would have in human cells is "significantly lower" than that seen in other experiments.

The results are a further boost to the listing of a company that, since the beginning of the pandemic, has been among the favorites of investors.

Its titles ended 2020 with a 50% revaluation, although there were times of the year when it exceeded 100% and touched 150 euros.

The arrival of vaccines made them lose steam, but 2021 and the new results have put the company back in the target of the markets.

Only in this month of January has it managed to match that 50% accumulated increase and its

capitalization reaches 1,980 million euros.

"The studies of PharmaMar and other companies such as the American

Gilead

were destined to cure the disease once it was infected, so the emergence of vaccines that would prevent precisely this situation significantly penalized their price. However, in the middle of the third wave, c

With the hospitals once again saturated

, and in view of the numerous obstacles that the different administrations are encountering to be able to vaccinate the population, this news has given new impetus to its price and has led it to exceed important levels in the graph ", explains

Aitor Méndez, an

analyst at IG Markets

.

At the head of the Ibex

The laboratory led the increases this Tuesday in the Ibex 35, ahead even of

Naturgy

, which advanced by around 15% due to the impulse of the offer of the IFM fund to acquire 22% of the company.

Banco

Sabadell, Merlin Properties and Meliá

are the other protagonists of the session, with increases of more than 3% that allow the selective gain more than 1% and touch 8,000 points again.

At the opposite extreme,

Solaria

(-7%),

Siemens Gamesa and Cellnex

are the worst values ​​of the day and prevent the Spanish index from approaching the increases of other European markets such as the Dax in Frankfurt (+1.9 %).

The Cac 40 in Paris (+ 1.4%), the Ftse Mib in Milan (+ 1.2%) and the Ftse 100 in London (+ 0.3%) also remain green despite the slowdown in the campaigns vaccination and the general increase in infections in Europe.

According to the criteria of The Trust Project

Know more

  • economy

  • Business

  • Coronavirus

  • Covid 19

Catalan doctors and Quim Torra criticize that the Generalitat does not increase restrictions against the coronavirus

The Generalitat will terminate the contract with Ferrovial to track the coronavirus in Catalonia

Coronavirus The Generalitat decrees the municipal confinement and new restrictions due to the negative data of the Covid in Catalonia

See links of interest

  • Holidays 2021

  • Spain - Hungary, live

  • Athletic Club - Getafe

  • FC Cartagena - Mirandés

  • Real Valladolid - Raise

  • Crystal Palace - West Ham United